Editorial: improved efficacy of biological maintenance therapy in "early" compared with "late" Crohn's disease: strike while the iron is hot with anti-TNF agents?
There is growing interest in the use of biologic therapy early in the course of Crohn's disease. In this issue, Schreiber et al. use data from the PRECISE trials to demonstrate a greater response to certolizumab in patients with shorter duration of disease. This suggests that early treatment prior to the occurrence of significant tissue remodeling and irreversible cumulative bowel damage may result in better outcomes. This editorial describes the data published so far on the correlation between disease duration and treatment response and examines the potential benefits to such treatment algorithms.
Ananthakrishnan
Ashwin N
AN
Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA.
Binion
David G
DG
D000465:Algorithms; D061067:Antibodies, Monoclonal, Humanized; D000068582:Certolizumab Pegol; D003424:Crohn Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D015337:Multicenter Studies as Topic; D010919:Placebos; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors
D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D007155:Immunologic Factors; D010919:Placebos; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol